Shilajit

Clinical Summary

Shilajit is a humic-substance exudate from Himalayan, Altai, Caucasus, Hindu Kush, and Andean rock formations — a heterogeneous phytocomplex of fulvic acid (60-80%), humic acid (15-20%), dibenzo-α-pyrones (DBPs), trace minerals (85+ elements), phenolic compounds, and triterpenes. It has no single molecular formula; composition varies by geography, altitude, and source biomass.

The clinical evidence base is narrow, single-sponsor-dominated, and rarely replicated. Of 9 PubMed-indexed human trials, 5 of 9 are tied to Natreon Inc. / PrimaVie (patented standardized extract). Zero Cochrane reviews exist. Zero medical society guidelines mention it. One systematic review (Morgado 2024, PMID 37697053) grades shilajit as "low-quality evidence, possibly effective for late-onset hypogonadism."

The strongest human signals are: testosterone modulation in middle-aged men (1 RCT, Pandit 2016), postmenopausal BMD preservation in osteopenia (1 RCT, Pingali 2022), sperm parameters in oligospermia (1 open-label trial, Biswas 2010 — not placebo-controlled), collagen synthesis biomarker elevation (1 RCT, Neltner 2024), and fatigue-induced strength preservation (1 RCT, Keller 2019). All are unreplicated by independent labs. The Martinez 2025 metabolic syndrome RCT (PMID 40573153, N=109, Kerry Group sponsored) used shilajit at only 6-12 mg as an adjunct to chromium + Phyllanthus emblica — shilajit's contribution is not isolable.

Who benefits most: (a) postmenopausal women with osteopenia (combined with vitamin D, calcium, weight-bearing exercise); (b) middle-aged men with confirmed low T; (c) oligospermic men trying to conceive; (d) select cases with iron-absorption issues.

Who gains little: young healthy eugonadal males seeking T-boosts (effect size ~20% on a single trial); cognitively intact people seeking MCI prevention (no human RCT exists); athletes seeking performance gains (only one open-label 28-day pilot with massive placebo risk, PMID 41613504); weight-loss seekers (no monotherapy trial).

Non-negotiable safety constraint: Raw/artisan resin without a batch-specific Certificate of Analysis (COA) carries documented heavy-metal contamination risk — lead, arsenic, mercury, cadmium, and newly detected thallium up to 0.5 µg/g in commercial supplements (PMID 39827344, Kamgar 2025). Use only third-party-tested, standardized extracts (PrimaVie and equivalents).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence. BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE caps at 2/5; Type=UCC caps at 3/5.

Dominant pattern: Every primary human indication is UCC (Unreplicated Causal) — single-trial evidence, never replicated by independent labs. The next tier down is SE (Surrogate Endpoint) — biomarker changes without clinical outcomes. Animal data is classed AHE (Animal→Human Extrapolation) and caps at 2/5. The whole evidence base is fragile: strongest claims rest on 1 RCT each, often industry-sponsored.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (/9). 7-9=strong | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor | WARN Signal — see Safety | AVOID Contraindicated

Star rating legend: 5/5 multiple large RCTs+meta | 4/5 several human RCTs | 3/5 single human RCT OR strong animal+pilot | 2/5 animal/very limited human | 1/5 theoretical/debunked.

Prescribing

Dosing Table

Formulation Table

Quality markers: USP Verified / NSF Certified / ConsumerLab (rare for shilajit); batch-specific COA showing heavy metals (Pb, Hg, As, Cd, Tl) <LOQ; fulvic acid content matching label; FTIR/HPLC fingerprint. Red flags: No COA on request, no geographic origin disclosure, gummy format, price under $15/mo for therapeutic dose, "cures cancer/reverses aging" claims.

Label accuracy is WORSE than contamination risk. ConsumerLab 2024 tested 8 popular brands: all passed heavy-metal safety thresholds at single-dose, but fulvic acid content varied by ~32,000% across products. Many capsule products were dramatically underdosed relative to label claim. Translation: the "is this product contaminated?" question is largely solved by tier-1 brand selection; the "does this product contain the labeled dose of active compound?" question is not — this is where most therapeutic failures originate. Demand fulvic acid assay on COA, not just heavy metals.

Condition-Specific Protocols

Postmenopausal Osteopenia Protocol

Evidence: 3/5 | Key PMID 35933897 (Pingali & Nutalapati 2022)

Phase 1: Initiation (Weeks 1-4)

• 250 mg/day purified extract AM with breakfast
• Confirm adequate D3 (serum 25(OH)D 40-60 ng/mL), dietary calcium 1000-1200 mg/day
• Baseline DEXA (lumbar spine, femoral neck, total hip) if not within 12 mo
• Baseline: CMP, eGFR, PTH, 25(OH)D, CTX-1, P1NP

Phase 2: Therapeutic (Weeks 5-24)

• Increase to 500 mg/day if 250 mg well-tolerated
• Weight-bearing + resistance exercise 3x/week minimum
• Repeat CMP at month 3
• Repeat CTX-1/P1NP at month 6 (expect reduced resorption, preserved formation)

Phase 3: Maintenance (Weeks 24-48+)

• Continue 500 mg/day
• DEXA repeat at 12-24 months
• Reassess annually: continue if BMD stable, reassess if continuing to lose bone

Drug interaction timing: Separate from levothyroxine by ≥4 h; separate from oral bisphosphonates by ≥4 h; separate from calcium supplements by 2 h.

Expected outcomes: Dose-dependent BMD preservation (not build) vs expected postmenopausal loss; reduction in 8-OHdG, MDA, CRP, IL-6 at 24-48 wk.

Stop/reassess: Continued BMD loss despite 12 mo of compliance → add bisphosphonate or other approved therapy. Rising creatinine > 0.3 mg/dL or K > 5.5 mEq/L → discontinue.

Male Fertility / Oligospermia Protocol

Evidence: 3/5 UCC (open-label, not RCT) | Key PMID 20078516

Phase 1: Initiation (Weeks 1-2)

• 100 mg processed shilajit with breakfast + 100 mg with dinner (200 mg/d total)
• Baseline: semen analysis (count, motility, morphology), total T, free T, FSH, LH, prolactin
• Rule out reversible causes: varicocele, Y-chromosome microdeletions, endocrine

Phase 2: Therapeutic (Weeks 3-12)

• Continue 200 mg/day
• Avoid scrotal heat (saunas, hot tubs, tight underwear)
• Adequate zinc (11 mg/d), selenium (55 µg/d), vitamin C, CoQ10 if oxidative stress markers elevated

Phase 3: Reassess (Week 13)

• Repeat semen analysis at 90 days (full spermatogenic cycle)
• Repeat T, FSH
• If improved: continue another 90 days for conception attempts
• If no change: stop; escalate to urologist / REI

Expected outcomes (per Biswas 2010, unreplicated, open-label): +61% total sperm count, +12-17% motility, +23.5% total T, +9% FSH, -19% semen MDA. Real-world effect likely smaller given open-label placebo risk.

Middle-Aged Male Hypogonadism Adjunct Protocol

Evidence: 3/5 UCC | Key PMID 26395129 (Pandit 2016), SR PMID 37697053 (Morgado 2024)

Phase 1: Initiation (Weeks 1-4)

• Baseline total T (morning, fasted), free T (equilibrium dialysis preferred), SHBG, LH, FSH, prolactin, PSA, CBC, CMP, lipid, HbA1c
• Confirm hypogonadism per AUA/Endocrine Society criteria: morning total T <300 ng/dL on 2 separate draws + symptoms
• Exclude reversible causes (OSA, obesity, zinc deficiency, opioids, SSRI, alcohol)
• 250 mg BID with meals

Phase 2: Therapeutic (Weeks 5-12)

• Continue 250 mg BID
• Sleep optimization, weight loss if BMI >27, resistance training

Phase 3: Reassess (Week 13)

• Repeat morning T
• If total T normalized and symptoms improved: continue
• If T unchanged and symptoms persist: stop shilajit, refer to endocrinology for TRT workup

Important distinction: Shilajit is NOT a replacement for TRT in confirmed hypogonadism requiring pharmacologic therapy. It is an adjunct/trial intervention for mild/subclinical presentations or men preferring non-hormonal approaches first.

Stop criteria: PSA rise >0.75 ng/mL/year, hematocrit >52%, new prostate symptoms → discontinue.

Safety

Interactions Table

Contraindications

Absolute:

• Severe renal impairment (eGFR <30 mL/min/1.73m² or dialysis) — mineral accumulation risk
• Pregnancy — no safety data; documented pseudohyperaldosteronism case (PMID 29933704)
• Lactation — unknown transfer; heavy-metal concern
• Documented heavy-metal toxicity
• Mast cell activation syndrome (MCAS) — anaphylaxis cofactor case (PMID 30863761)

Relative:

• Moderate CKD (eGFR 30-59) — reduce dose 50%, monitor quarterly
• Hemochromatosis / iron overload — fulvic acid may enhance iron absorption
• Elevated ferritin / iron accumulation risk — anyone with ferritin >200 ng/mL, HFE gene variants, or males >40 without regular blood loss (menstruation, donation, clinical bleeding). Shilajit contains bioavailable iron AND fulvic acid enhances iron absorption — a mechanistic double-hit on iron stores. Check ferritin + TSAT baseline if any of these apply; recheck at 3-6 mo. Under-discussed in both clinical literature and community discourse.
• Hypercalcemia / hyperkalemia
• Hormone-sensitive prostate conditions (BPH, prostate cancer history) — testosterone-elevating effect; oncologist approval required
• Hormone-sensitive breast cancer — precautionary; no data
• Uncontrolled diabetes (HbA1c >10%) without medical oversight
• Known licorice sensitivity / pseudohyperaldosteronism risk (rare humic-substance reaction)
• Polypharmacy supplement stacks (esp. thermogenic/PED-adjacent) — PMID 39742323 reports a 2024 CVST case in a bodybuilder on a multi-supplement stack; shilajit was present but not the primary suspect. Generic caution: do not combine with high-dose nitric oxide boosters, anabolic-adjacent herbals, and large mineral loads without bloodwork and physician oversight.

Adverse Effects (ranked by frequency)

Common (>1%):

• GI upset — nausea, abdominal discomfort, loose stools (5-10%). Dose-dependent. Management: take with food, reduce dose, switch to capsule form.
• Dark urine (3-5%) — benign fulvic acid metabolite; not hematuria unless confirmed.
• Taste aversion — earthy/tar/asphalt/pungent; dominant community complaint for resin form.

Uncommon (0.1-1%):

• Headache, dizziness
• Insomnia / overstimulation if dosed late (community-reported)
• Mild hypoglycemia if on diabetes medications

Rare (<0.1%) — but serious:

• Pseudohyperaldosteronism / licorice-like syndrome (PMID 29933704 Stavropoulos 2018) — case report in pregnancy; mechanism = glycyrrhizin-like 11β-HSD2 inhibition by humic substances. Single case but mechanistically plausible.
• Exercise-induced anaphylaxis with shilajit as cofactor (PMID 30863761 Losa 2019) — in patient with underlying MCAS.
• Heavy-metal toxicity (unpurified/contaminated products) — fatigue, cognitive impairment, abdominal pain, anemia. Prevention: only COA-verified products.
• Hyperkalemia — theoretical, in renal impairment.

Preprint-tier safety signal (NOT peer-reviewed):

• Mamadaliyev 2025 (Andijan State Medical Institute, Uzbekistan — Zenodo preprints 10.5281/zenodo.17902135, .17917848, .17922272): chronic mumijo 100 mg/kg in 5 dogs over 6 days prolonged clotting time, plasma recalcification time, thrombin time, heparin time. Anticoagulant-interaction signal — biologically plausible (humic substances are polyanionic and may bind clotting factors) but unreplicated in humans. Flag, don't act as if confirmed.

FAERS Signal Table (from BioMCP)

Summary: 11 total FAERS reports for shilajit; 0 primary-suspect; 11/11 concomitant. 10 reports for fulvic acid — same pattern. 1 report for PrimaVie (ibrutinib primary). FAERS is effectively noise for shilajit — consistent with the broader FAERS supplement-noise pattern. No actionable pharmacovigilance signal from FDA's adverse event database. Clinically relevant safety signals exist in the medical literature (case reports above, contamination studies), not in FAERS.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Animal NAFLD/APAP data suggests hepatoprotection; this does not validate safety in human cirrhosis. Use under hepatologist supervision or skip.

Synergies & Stacking

Antagonisms:

• High-dose iron / calcium / zinc taken simultaneously → competitive chelation; space by 2-3 hours
• Levothyroxine → mineral chelation; separate by 3-4 hours
• Coffee/tea (minor) → no documented interaction at typical doses

Wikilinks to active health files: Vitamin D3, Calcium, CoQ10, Ashwagandha, Tongkat Ali, Zinc, Vitamin B Complex, Iron.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Overall: No genotype-based dosing is warranted. This is a genuine research gap. Pharmacogenomics of humic substances is unexplored territory as of 2026.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, influencer hype, and recall bias are inherent. Presented for completeness.

Dominant Sentiment

Mixed-positive, with significant skeptic minority. Across r/Nootropics, r/Supplements, r/Testosterone, Longecity, Bodybuilding.com, Bluelight, and YouTube/TikTok discourse, ~60-70% of users self-report mild-to-moderate subjective benefits at 250-500 mg/day; ~25-40% report "meh" / "maybe placebo" / no effect. 2024-2026 saw explosive TikTok trend (500M+ views, 27K+ monthly US searches for "shilajit gummies") primarily in young-male fitness/alpha niche.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Less prominent than essential oils/greens; some MLM structures exist in wellness-stack promotion but not dominant. Cautionary precedent: Black Oxygen Organics (BOO) — adjacent fulvic-acid MLM selling Ontario peat-bog "humic dirt" — was recalled by Health Canada and FDA in 2021 for elevated lead/arsenic and collapsed amid class-action lawsuits. The humic-substance category can scale contamination fast via MLM; watch for similar patterns in shilajit.
• Influencer concentration: HIGH for 2024-2026. Joe Rogan (confirmed user; JRE endorsement is a major demand driver). Andrew Huberman NOT publicly endorsing — often falsely conflated with his Fadogia/Tongkat protocol. Peter Attia, Chris Masterjohn, Mark Sisson: silent (conspicuous by omission)
• Astroturfing signals: SEO content spam (Cymbiotika alone publishes dozens of near-identical blog posts); TikTok comment sections with similar-phrased positive reviews; Amazon 5-star reviews with patterns
• Commercial bias: Positive reports in influencer content strongly correlated with affiliate links and discount codes; authentic COA-backed reviews drowned out by marketing volume
• Gummy format: universally panned by informed users as underdosed marketing product — but dominates mainstream adoption
• Scam/refund issues: Trustpilot complaints common for Pure Himalayan Shilajit, Xarashilajit, Mystic Shilajit (non-delivery, refund failures, 2024-2025)
• Folk purity tests (water dissolve, flame test, "linga" burn test) are myths — only lab COA can establish purity
• Brand proliferation: hundreds of Amazon/Etsy/Shopify white-label brands without independent heavy-metal testing
• Label accuracy crisis: ConsumerLab 2024 tested 8 brands → all passed heavy-metal thresholds but fulvic acid content varied by ~32,000% between products. Many capsules dramatically underdosed relative to label. Therapeutic failures in the community are more often a dosing/content problem than a "shilajit doesn't work" problem

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: modest energy/libido effects at 250-500 mg/day, taste aversion, GI sensitivity, need for 4-8 week timeline, PrimaVie being gold-standard. Diverges on: effect size (community reports ~20% "edge" matching Pandit's T-study, but TikTok marketing implies dramatic transformation), hair reversal claims (community echoes marketing, no evidence), gummy adequacy (community correctly skeptical against marketing), "Huberman endorsement" (community myth, not reality). Most likely explanations for divergence: placebo × affiliate-marketing amplification × wellness-trend social proof.

Deep Dive: Mechanisms & Research

Chemistry (Primary Bioactives)

• Fulvic acid (60-80%): Low-MW (300-3000 Da, predominantly 500-1500 Da) polyphenolic humic substance with -COOH, -OH, and phenolic groups. Primary electron carrier / shuttle; mineral chelator; antioxidant.
• Humic acid (15-20%): Higher-MW aromatic polymers; water-insoluble in acid, soluble in alkali.
• Dibenzo-α-pyrones (DBPs): Urolithin-analog bicyclic aromatics; putative antioxidant and mitochondrial modulators. PrimaVie is DBP-standardized.
• Phenolic acids, triterpenes, sterols: Variable by geography (Iranian vs Himalayan vs Altai vs Andean differ by orders of magnitude in phenolic-acid content — PMID 41699045).
• Trace minerals (~65-85 elements): Iron, calcium, magnesium, zinc, selenium, copper, manganese, potassium — AND often Pb, Hg, As, Cd, thallium (contamination).

Mechanisms with Clinical Translation

• Mitochondrial electron transport: Fulvic acid as electron shuttle; preserves ETC Complex I/II/III activity and mitochondrial membrane potential (rat CFS model, PMID 22771318). Translates to human fatigue-resistance signal (PMID 30728074 Keller 2019).
• Steroidogenesis (3β-HSD, 17β-HSD): Enhances Leydig cell enzyme activity; translates to T increase in Pandit 2016 (PMID 26395129) and sperm/T in Biswas 2010 (PMID 20078516). Restored in cyclophosphamide-damaged mouse testes (PMID 39121783).
• Antioxidant (Nrf-2 / SOD / catalase / GPx): Direct free-radical scavenging + Nrf-2 pathway upregulation. Translates to reduced 8-OHdG, MDA in humans (Pingali 2022).
• Anti-inflammatory (NF-κB / TNF-α / IL-6): Reduced CRP, IL-6 at 48 wk in Pingali 2022; animal NAFLD models show cytokine reduction.
• Collagen synthesis (COL1A1, COL1A2, COL3A1): Muscle transcriptome PMID 27414521, skin PMID 31161927, serum Pro-C1α1 biomarker PMID 36546868.

Mechanisms Still Speculative (Clinical Translation Pending)

• Tau aggregation inhibition: In-vitro Andean shilajit (PMID 37513872) and mechanistic reviews (PMID 23131823, 35204750, 32651325). No human AD/MCI RCT.
• Adiponectin/resistin modulation: Rat NAFLD only (PMID 35258780).
• 11β-HSD2 inhibition (pseudoaldosteronism mechanism): Explains rare case report (PMID 29933704) — humic substances functionally mimic glycyrrhizin.
• Coagulation modulation: Dog preprint (Mamadaliyev 2025) — polyanionic humic substances theoretically bind clotting factors. Not human-validated.
• SIRT2/SIRT3 upregulation (nephroprotection): Rat 5-FU model (PMID 40666183).
• Osteogenic bone formation (beyond resorption blockade): Rat tibial defect + xenograft (PMID 41157202); isolated boswellic-acid analogs docked to ERα/Cathepsin K (PMID 41297104).

Pharmacokinetics

Severely limited human data. No comprehensive PK study tracking fulvic acid, DBPs, or mineral constituents over time. Inferred:

• Absorption: fulvic acid primarily jejunum/ileum, paracellular + transcellular
• First pass: minimal hepatic transformation; fulvic acid largely intact
• Tmax: 2-4 h (estimated from downstream biomarker changes)
• Elimination: primarily renal, 24-48 h
• Mineral dissociation: chelated minerals release in acidic stomach, re-form in small intestine

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Registered: 8 | Completed: 7 | Active/Recruiting: 0 | Published: 3. Total lifetime N across all trials: ~256. Indian CTRI registry is likely to contain additional entries not mirrored to ClinicalTrials.gov (manual search required). Iranian IRCT holds Sadeghi 2020 tibia fracture trial (PMID 32310691).

Regulatory Status (from BioMCP + web research)

• FDA (US): DSHEA dietary supplement — no pre-market approval, no FDA-approved indication. FDA-Philippines issued 2025 public health warning 2025-1407 on unregistered Kirkland Signature shilajit product.
• EMA / EU: Mumijo/shilajit classed as NOT novel for food supplements but IS novel for other food categories under Regulation 2015/2283.
• Australia TGA: Not on ARTG — sale, supply, and advertising as a therapeutic good is unlawful. Personal importation scheme only.
• WADA: Not prohibited on 2025 list. Not listed by NSF Certified for Sport or Informed Sport (contamination risk).
• India (AYUSH / CDSCO): Monographed in Ayurvedic Pharmacopoeia of India as Shilajatu — quality/identity standard under Drugs and Cosmetics Act 1940. Not a scheduled drug; OTC.
• Regulatory context: The absence of FDA approval reflects supplement/business classification, not a specific safety finding. The thallium detection (PMID 39827344) and regional heterogeneity (PMID 40223103, 41699045) represent the dominant regulatory concerns — product variability, not compound class safety.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature — "natural Himalayan exudate" marketing; nature-biased bias
• Appeal to tradition — "centuries of Ayurvedic use" — tradition ≠ efficacy; survivorship-biased
• Appeal to authority — Joe Rogan endorsement + misattributed "Huberman use"; PrimaVie repeatedly cited as though independent
• Hasty generalization — animal NAFLD/APAP data → human liver disease recommendations; rat CFS → human CFS
• Cherry-picking — Natreon RCTs highlighted; Martinez 2025 null-ish combo trial rarely discussed in marketing
• Argument from popularity — 500M TikTok views ≠ clinical effect
• Confusion of biomarker and clinical outcome — collagen Pro-C1α1 and 8-OHdG are surrogates, not outcomes (see vitamin E precedent)
• "Alpha male" / "ancient secret" mythic framing — marketing-driven, not evidence-driven

Evidence Gaps

• Zero independent replication of any of the 4 PrimaVie-sponsored Western RCTs
• Zero meta-analyses exist (file correctly notes this)
• Zero Cochrane reviews
• Zero medical society guidelines
• No head-to-head RCTs vs ashwagandha, tongkat ali, or TRT for T-boost
• No human PK study
• No pharmacogenomics data
• No sex-stratified analysis in Martinez 2025 mixed-sex trial
• No premenopausal female data for any indication
• No pediatric / pregnancy / lactation safety data
• No long-term safety beyond 48 weeks
• Product heterogeneity unacknowledged in most marketing — Iran/India/Nepal/Kyrgyzstan/Russia samples differ by orders of magnitude in phenolic acid content (PMID 41699045, 40223103)
• No dedicated human trials for: cognition, sleep, mood, independent fatigue, hair, skin aging, iron-deficiency anemia, altitude, immune, osteoarthritis — all heavily marketed

Bias Flags (Mode 4: First Principles)

• Single-vendor RCT capture: Natreon/PrimaVie is the suspect drug in 5 of 9 PubMed human trials; Kerry Group and Vedic Lifesciences (Indian CRO) cover the rest. Mayo Clinic is the sole independent academic sponsor — and tested Cystone, a 9-herb formulation, not isolated shilajit.
• Publication venue concerns: TruBlk pilot (PMID 41613504) in Cureus (minimal peer review); coagulation signal in Zenodo preprints only.
• Geographic sampling bias: most chemistry data from Iran/India; Andean shilajit program (Maccioni group in Chile) drives all the AD/tau literature with overlapping authorship.
• Industry repeats: Das 2016, Das 2019, Keller 2019, Neltner 2024 all involve Natreon-supplied product and overlapping author lists (Roy, Gordillo, Veeraragavan).
• Mumijo ≠ shilajit ≠ ZhaXun nomenclature confusion: Russian/Uzbek mumijo, Tibetan ZhaXun, Andean shilajit, Himalayan shilajit, Iranian momiai have different chemistry; cross-cultural extrapolation is a hidden bias in the literature.
• Open-label dominance in the positive data: oligospermia (Biswas 2010), TruBlk 2026 (Yadav), Uzbek COVID fulvic trial — highest effect sizes come from least-controlled designs.
• Predatory-tier systematic review laundering: A 2024 "Systematic Review of Shilajit: Clinical Efficacy and Safety" in J Popul Ther Clin Pharmacol applied the Cochrane RoB tool to 15 heterogeneous studies and reached positive conclusions; the journal is predatory-tier and the methodology is weak. Be skeptical of citations to this SR — the legitimate SR remains Morgado 2024 (PMID 37697053), which rates shilajit LOW quality.
• Russian humic-substance literature overclaim pattern: PMID 41515410 (Zykova & Belousov 2025, Molecules) — flagship Russian pharmacology review claims immunotropic, antiviral, antitumor, hepatoprotective, regenerative, detox, adaptogenic effects AND "absence of toxic and allergenic properties." This totalizing "safe and effective for everything" framing is a known Russian/Soviet phytopharmacology bias; requires Western replication and skeptical discount.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: PrimaVie trademark ubiquity in premium-wellness branding; "clinically studied" language omits "single small industry RCT"; Indian brand ecosystem (Dabur, Himalaya, Zandu) large and uncontrolled for Western COA standards
• Influencer economics: Joe Rogan is a real user and his endorsement is a major demand driver; affiliate economy around shilajit gummies is extensive; undisclosed sponsorships common on TikTok. Andrew Huberman has NOT endorsed despite frequent misattribution — this is itself a marketing phenomenon
• Counter-narrative manipulation: Heavy-metal fearmongering sometimes weaponized to promote specific "pure" brands; legitimate contamination science (Kamgar 2025) co-opted as sales tool
• Cautionary precedent (Black Oxygen Organics, 2021): Not shilajit but adjacent — Canadian MLM sold "fulvic acid humic dirt" from an Ontario peat bog as a panacea. Recalled by Health Canada and FDA for elevated lead and arsenic, class-action lawsuits followed, company folded November 2021. The fulvic-acid / humic-substance category can scale heavy-metal contamination fast via MLM distribution. No major shilajit-specific MLM has reached BOO scale (yet), but the template exists and warrants vigilance — especially as 2024-2026 TikTok-driven demand pulls inexperienced brands into the market.
• Counterfeit resin specifics: documented substitutes include shoe polish, coal tar, asphalt, and generic humus mixtures. Tells: chemical/petroleum odor, grainy texture, no water solubility, no melt response to warm hands, unusually low price. Capsules and tinctures are easier to fake than resin; paradoxically, resin is easier to visually vet but harder to lab-verify without third-party testing.
• Cui bono summary: Shilajit popular ⇒ wins: Natreon (PrimaVie licensing to dozens of finished brands), Kerry Group, Indian supplement conglomerates (Dabur, Himalaya, Patanjali, Zandu), hundreds of Amazon white-label brands, TikTok creators with affiliate deals, Joe Rogan-adjacent supplement economy. Shilajit NOT popular ⇒ wins: limited — no specific pharma drug competes with shilajit; testosterone-boosting prescription therapies (TRT clinics) compete mildly; a minor natural-skepticism niche of science communicators profits from debunking content
• Red team highlight (most concerning angle): The single-vendor evidence capture — 56% of Western RCTs use PrimaVie supplied by the sponsoring company — is the canonical pattern of a nutraceutical with industrial capture of its own RCT pipeline. Comparable to Sensoril ashwagandha (also Natreon), KSM-66 ashwagandha (Ixoreal), TA-65 (T.A. Sciences). This pattern historically precedes independent-lab failed replications when they eventually occur.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 — Real but narrow human signal in 3 indications; single-trial evidence for each; strong mechanistic plausibility; substantial cross-domain breadth (bone, andrology, muscle, liver, kidney, cognition) but mostly at 2/5 AHE level; notable contamination and industry-capture risk. Compound-intrinsic score; NOT evaluated against any existing stack.

• Opportunity cost: Moderate. ~$30-60/mo for quality product. Mineral chelation requires 2-4 hour spacing from many other supplements and medications, complicating stack design. Taste is a compliance obstacle for resin users. Heavy-metal contamination risk requires ongoing COA vigilance.

• Hell-yes-or-no (Sivers): Not a hell yes. Evidence too narrow and too single-sponsor.

• Regret minimization: In 5 years, the regret would be documenting this compound WITHOUT flagging the PrimaVie-capture pattern, the thallium finding, the pseudohyperaldosteronism case, and the preprint coagulation signal. Those are the load-bearing updates for anyone who might use this.

• Verdict: CONDITIONAL

• Conditions (CONDITIONAL warrants use):

  1. Postmenopausal woman with DEXA-confirmed osteopenia (T-score -1.0 to -2.5) + adequate D3 + calcium + weight-bearing exercise (Pingali 2022 protocol)
  2. Middle-aged male with biochemically confirmed hypogonadism (2 morning total T <300 ng/dL) who prefers non-pharmacologic trial before TRT, with 90-day reassessment
  3. Oligospermic male actively trying to conceive (partner workup done; varicocele excluded) with 90-day trial before escalation to REI
  4. Purified standardized extract (≥50% fulvic acid) from a vendor providing a batch-specific COA showing heavy metals (including thallium) <LOQ. Non-negotiable.

  SKIP otherwise. Do not use for general energy/libido optimization without labs. Do not use gummies. Do not use raw resin without COA. Do not use in pregnancy, severe CKD, or MCAS.

Bottom Line

Shilajit has genuine but thin human evidence for narrowly defined clinical use cases, entangled with a single-vendor (Natreon/PrimaVie) RCT pipeline, explosive 2024-2026 TikTok hype outrunning the data, and legitimate heavy-metal contamination concerns (including newly detected thallium, PMID 39827344). CONDITIONAL use warranted only with confirmed indication, confirmed product quality, and defined stop criteria. For most healthy people seeking vague "vitality" benefits: not worth the cost, attention, and contamination risk. For postmenopausal osteopenia, confirmed hypogonadism, or oligospermia: worth a 90-day trial with appropriate monitoring and product vetting.

Practical Notes

Brands & Product Selection

Gold standard: PrimaVie (Natreon Inc.) — DBP-standardized, ≥50% fulvic acid, heavy-metal-tested, licensed to multiple finished-product brands. Used in 5/9 Western human RCTs. Most Nootropics Depot shilajit capsules use PrimaVie.

Acceptable if COA-verified: Lotus Blooming Herbs (traditional Ayurvedic purification); Pure Himalayan Shilajit (mixed Trustpilot signals, scam complaints 2024-2025 — verify batch COA); Sunfood Superfoods (COA on website); Indian brands Dabur / Himalaya / Zandu (dominant in South Asia, variable Western COA practice).

Red flags:

• No batch-specific COA on request
• Gummy format (underdosed, community-panned)
• Amazon/TikTok/Etsy white-label brands without third-party testing
• Prices under $15/mo for 500 mg/d therapeutic dose
• "Cures cancer" / "reverses aging" / "ancient secret" marketing
• No geographic origin disclosure (Himalayan, Altai, Andean, Iranian — all have different chemistry, PMID 41699045)
• No contact information for manufacturer
• Trustpilot non-delivery / refund complaints (Pure Himalayan Shilajit, Xarashilajit, Mystic Shilajit have documented patterns 2024-2025)

CoA must show: Heavy metals (Pb, Hg, As, Cd, Tl) <LOQ, microbial (TAC, yeast/mold, E. coli, Salmonella), fulvic acid content matching label, identity (FTIR or HPLC fingerprint).

Storage & Handling

• Temperature: Room temp (15-25°C); avoid >30°C (degrades fulvic acid)
• Light: Amber glass or original container
• Humidity: Dry; resin forms clump and may promote microbial growth if humid
• Shelf life: Purified extract 2-3 y unopened / 18-24 mo opened; raw resin claimed indefinite but 2-3 y recommended

Palatability & Compliance

Resin taste is a frequent deal-breaker — community-described as "tar," "asphalt," "cow urine," or "pungent earth." Authentic shilajit IS pungent (a heuristic many "is-it-real" guides get backwards). Mixing strategies: warm (not boiling) water dissolves best; can mix with honey, herbal tea, smoothie, or coffee substitute. Capsules bypass taste entirely and are often preferable for long-term compliance. Compliance matters more than form. The #1 determinant of efficacy is whether you actually take it for 90+ days.

Exercise & Circadian Timing

• AM with breakfast preferred: aligns with cortisol awakening response; sustained energy through day; avoids reported evening overstimulation
• Pre-workout (60-90 min before): mitochondrial ATP support, reduced fatigue signal (Keller 2019)
• Post-workout: collagen synthesis support (Neltner 2024 Pro-C1α1 data; Das 2016 exercise synergy)
• Avoid late evening if prone to sleep disruption — community signal, no RCT data on sleep

Reference Ranges (Expected Biomarker Changes)

Cost

Best value: COA-verified capsule ~$25/mo. Premium: PrimaVie ~$40-50/mo. Avoid: raw resin without COA (unquantified heavy-metal exposure), gummy format (underdosed).

What We Don't Know

• Whether any PrimaVie RCT result replicates in an independent academic lab (2026: none has)
• Human pharmacokinetics (fulvic acid, DBPs, mineral components) over time
• Long-term (>48 week) safety and durability of effect
• Whether the coagulation signal from the Uzbek dog preprint (Mamadaliyev 2025) translates to humans — potentially important for anyone on warfarin / DOACs / antiplatelets
• Whether thallium levels in commercial supplements (up to 0.5 µg/g, PMID 39827344) have cumulative toxicity significance at therapeutic dosing over years
• Effect size and safety in premenopausal women (entirely absent from the trial base)
• Pregnancy / lactation / pediatric safety (the pseudohyperaldosteronism case PMID 29933704 is a single n=1 but mechanistically plausible)
• Pharmacogenomic modifiers of response (SOD2, GPX1, HSD3B1, FUT2, ABO) — unexplored
• Whether Andean shilajit's tau-aggregation inhibition translates to any human cognitive endpoint
• Whether the nutraceutical-market 2024-2026 TikTok surge degraded average product quality (demand outstripping COA-verified supply) — ConsumerLab 2024 32,000% fulvic-acid variance suggests yes, but this is a label-accuracy question, not a contamination question
• Head-to-head ranking vs ashwagandha, tongkat ali, TRT, or fadogia agrestis for testosterone
• Whether the mumijo / ZhaXun / shilajit / momiai nomenclature conflation hides genuinely different chemistry with different effect profiles

References

Systematic Reviews & Traditional Reviews

• Morgado A et al. (2024). Do testosterone boosters really increase serum total testosterone? A systematic review. Int J Impot Res. PMID: 37697053 — PrimaVie shilajit graded LOW quality, "possibly effective" only for late-onset hypogonadism.
• Stohs SJ. (2014). Safety and efficacy of shilajit (mumie, moomiyo). Phytother Res 28(4):475-479. PMID: 23733436 — fulvic acid and DBPs identified as key bioactives.
• Wilson E et al. (2011). Review on shilajit used in traditional Indian medicine. J Ethnopharmacol 136(1):1-9. PMID: 21530631 — critical review; calls for rigorous trials.
• Das A et al. (2026). Preclinical efficacy of shilajit in cancer: a systematic review. Cureus. PMID: 41640940 — 9 preclinical studies, zero eligible clinical trials.

Landmark Human Trials (All Single-Trial Evidence)

• Pandit S et al. (2016). Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia 48(5):570-575. PMID: 26395129. RCT N=75, 250 mg BID × 90 d, ↑ total T, free T, DHEAS.
• Biswas TK et al. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia 42(1):48-56. PMID: 20078516. Open-label N=35, 100 mg BID × 90 d, ↑ sperm count 61%, T 23.5%.
• Pingali U, Nutalapati C. (2022). Shilajit extract reduces oxidative stress, inflammation, and bone loss in postmenopausal women with osteopenia. Phytomedicine 105:154334. PMID: 35933897. RCT N=60, 250 or 500 mg/d × 48 wk, dose-dependent BMD preservation.
• Neltner TJ et al. (2024). Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1alpha1. J Diet Suppl 21(1):1-12. PMID: 36546868. RCT N=63, 500 vs 1000 mg/d, 75% responders at high dose.
• Keller JL et al. (2019). Shilajit on fatigue-induced muscular strength and hydroxyproline. J Int Soc Sports Nutr 16(1):3. PMID: 30728074. RCT N=63, 500 mg/d PrimaVie × 8 wk.
• Das A et al. (2016). Human Skeletal Muscle Transcriptome in Response to Shilajit. J Med Food 19(7):701-709. PMID: 27414521. Transcriptome study; exercise synergy.
• Das A et al. (2019). Skin Transcriptome of Middle-Aged Women Supplemented With Shilajit. J Am Coll Nutr 38(6):526-536. PMID: 31161927. Microperfusion + ECM genes.
• Sadeghi Z et al. (2020). Momiai (Iranian mumijo) in tibia fracture repair. J Altern Complement Med. PMID: 32310691. RCT N=160, 1000 mg/d, union 129 vs 153 d.
• Yadav et al. (2026). Open-label TruBlk shilajit resin, physical performance. Cureus. PMID: 41613504. Open-label, single-arm, N=25, no placebo — interpret cautiously.
• Martinez L et al. (2025). Cr + Phyllanthus emblica + shilajit (6-12 mg) in metabolic syndrome. Nutrients. PMID: 40573153. RCT N=109 completers; shilajit NOT isolable.

Animal / Mechanism Studies

• Surapaneni DK et al. (2012). Shilajit modulates HPA axis and mitochondria in rat CFS model. J Ethnopharmacol 143(1):91-99. PMID: 22771318.
• Ghezelbash B et al. (2020). Hepatoprotective effects of shilajit in rat NAFLD. Horm Mol Biol Clin Investig 41(1). PMID: 32083445.
• Ghezelbash B et al. (2022). Shilajit modulating resistin, adiponectin, cytokines in rat NAFLD. Chin J Integr Med 28(6):531-537. PMID: 35258780.
• Ghasemkhani N et al. (2021). Shilajit on aspirin-induced gastric lesions in rats. Physiol Rep 9(7):e14822. PMID: 33818003.
• Rajpoot V et al. (2024). Shilajit reversed cyclophosphamide testicular damage in mice. J Ayurveda Integr Med. PMID: 39121783.
• Ezer A et al. (2025). Shilajit vs 5-FU nephrotoxicity; SIRT2/SIRT3 in rats. Iran J Basic Med Sci. PMID: 40666183.
• He et al. (2026). ZhaXun/shilajit vs APAP liver injury in mice. J Ethnopharmacol. PMID: 40957543.
• Guler et al. (2025). Rat tibial defect bone regeneration with shilajit + xenograft. Life. PMID: 41157202.
• Alqarni A et al. (2025). Shilajit in periodontal ligament wound healing (in vitro). BMC Complement Med Ther. PMID: 40057709.
• Aziz et al. (2026). Boswellic-acid analogs from shilajit; ERα/Cathepsin K docking. J Pharm Biomed Anal. PMID: 41297104.
• Andrade V et al. (2023). Andean shilajit fractions inhibit tau aggregation in rat neurons. Pharmaceuticals. PMID: 37513872.
• Ding et al. (2024, 2020). Tibetan ZhaXun quality control via HPLC/FTIR/GANs. PMID: 39624838, 32612671.

Disease-Relevant Reviews

• Carrasco-Gallardo C et al. (2012). Shilajit + B vitamins in Alzheimer's prevention. Arch Med Res 43(8):699-704. PMID: 23131823.
• Maccioni / Calfio et al. Alzheimer's + shilajit reviews. PMID: 35204750, 32651325.
• 2026 review: shilajit as DMOAD (disease-modifying osteoarthritis drug) candidate. PMID: 41904894.
• Ricottini E et al. (2024). Nutraceutical combo (with shilajit) for metabolic syndrome. Nutrients. PMID: 39683371.

Contamination, Chemistry, Safety

• Hussain A, Saeed A. (2024). Heavy metals and humic substances in shilajit. Biol Trace Elem Res 202(12):5794-5814. PMID: 38393486.
• Kamgar E et al. (2025). Thallium quantification in shilajit and supplements — up to 0.5 µg/g; concentration in some supplements was HIGHER than in crude shilajit, implicating processing/adulteration. BMC Chem 19(1):20. PMID: 39827344.
• Kamgar E et al. (2025). Chloride, sulfate, nitrate in raw shilajit samples across 5 regions. PMID: 40223103.
• Kamgar E et al. (2026). Phenolic acid HPLC-MS/MS across regions. Sci Rep. PMID: 41699045.
• Basavaraja et al. (2025). Chemical characterization of native Himalayan resin. ACS Omega. PMID: 41404054.
• Kohli et al. (2026). Raw vs extract vs resin phytocomplex comparison. J Chromatogr A. PMID: 41330163.
• Kamgar et al. (2025). Comprehensive chemistry review. Crit Rev Anal Chem. PMID: 38133965.
• Aldakheel et al. (2022). Heavy metal load review. PMID: 34800280.
• Stavropoulos et al. (2018). Pseudohyperaldosteronism due to mumijo consumption during pregnancy — licorice-like syndrome, 11β-HSD2 inhibition. Case report. PMID: 29933704.
• Losa F et al. (2019). Exercise-induced anaphylaxis with shilajit as cofactor in MCAS patient. World J Clin Cases 7(5):623-627. PMID: 30863761.
• Williams JC et al. (2025). Humic/fulvic + EGCG + vit C in nursing-home COVID (non-isolable). Cureus. PMID: 39925527.
• Zhernov YV et al. (2021). Humic substances and shilajit vs HIV-1 in vitro. PLoS One. PMID: 33065073.
• Socol. (2022). Humic acid antiviral activity review. PMID: 36712657.
• Mamadaliyev A et al. (2025). Chronic mumijo prolongs clotting/thrombin/heparin times in dogs. Andijan State Medical Institute, Uzbekistan. Zenodo preprints: 10.5281/zenodo.17902135, 10.5281/zenodo.17917848, 10.5281/zenodo.17922272. NOT peer-reviewed — flag for anticoagulant interaction caution.
• Zykova MV, Belousov MV et al. (2025). Humic substances: pharmacological review — immunotropic, antiviral, antitumor, hepatoprotective, regenerative, detox, adaptogenic effects (Russian pharmacology perspective). Molecules. PMID: 41515410. Read with skepticism re: totalizing safety claims.
• Humic substances biomedical applications review. Antioxidants 2025. PMID: 41009043.
• Fulvic acid protects against amoxicillin/clavulanate hepatotoxicity in rodents. 2025. PMID: 41494743.
• Humic substances molecular signaling mechanisms. 2026. PMID: 41944950.
• Supramolecular complexes of humic substances. 2026. PMID: 41599244.
• Root-canal sealer AH Plus + 0.5%/6% shilajit — ISO 6876 properties maintained. 2024. PMID: 38504287.
• Shilajit-based doxorubicin nanocarrier (oncology delivery vehicle). 2024. PMID: 38628801.
• CVST case in a bodybuilder on a supplement stack (shilajit present, not primary suspect). 2024. PMID: 39742323.

External Resources

• Examine.com Evidence Summary: https://examine.com/supplements/shilajit/ (independent third-party analysis)
• Ayurvedic Pharmacopoeia of India (AYUSH): Shilajatu monograph
• ClinicalTrials.gov: 8 NCT entries (see Deep Dive section)
• India CTRI (Clinical Trials Registry India): manual search recommended for additional trials not mirrored to ClinicalTrials.gov
• FDA-Philippines Public Health Warning 2025-1407 (Nov 2025) — unregistered Kirkland Signature shilajit

Last reviewed: 2026-04-17 | Next review: 2026-10-17 or sooner if major RCT publishes